Clinical Trial Update: Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating radiotherapy followed by durvalumab and ceralasertib in stage III non-small cell lung cancer patients who relapsed after th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ceralasertib (ceralasertib)
• Durvalumab (durvalumab)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Non Small Cell Lung Cancer NSCLC | Phase 2 | Status: RECRUITING